Interactions of Human Melanocortin 4 Receptor with Nonpeptide and Peptide Agonists,
Open accessThe DOI matches its Crossref record; 81 of the 81 references it cites were found in a registry or an index.
Abstract
Specific interactions of human melanocortin-4 receptor (hMC4R) with its nonpeptide and peptide agonists were studied using alanine-scanning mutagenesis. The binding affinities and potencies of two synthetic, small-molecule agonists (THIQ, MB243) were strongly affected by substitutions in transmembrane alpha-helices (TM) 2, 3, 6, and 7 (residues Glu(100), Asp(122), Asp(126), Phe(261), His(264), Leu(265), and Leu(288)). In addition, a I129A mutation primarily affected the binding and potency of THIQ, while F262A, W258A, Y268A mutations impaired interactions with MB243. By contrast, binding affinity and potency of the linear peptide agonist NDP-MSH were substantially reduced only in D126A and H264A mutants. Three-dimensional models of receptor-ligand complexes with their agonists were generated by distance-geometry using the experimental, homology-based, and other structural constraints, including interhelical H-bonds and two disulfide bridges (Cys(40)-Cys(279), Cys(271)-Cys(277)) of hMC4R. In the models, all pharmacophore elements of small-molecule agonists are spatially overlapped with the corresponding key residues (His(6), d-Phe(7), Arg(8), and Trp(9)) of the linear peptide: their charged amine groups interact with acidic residues from TM2 and TM3, similar to His(6) and Arg(6) of NDP-MSH; their substituted piperidines mimic Trp(9) of the peptide and interact with TM5 and TM6, while the d-Phe aromatic rings of all three agonists contact with Leu(133), Trp(258), and Phe(261) residues.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“They concluded that the HFRW sequence of NDP-MSH was required to form a β-hairpin-like structure so that the phenyl ring of Phe 7 interacts with the indole ring of Trp 9 (Figure 3B).”
From ACTH Antagonists (2016) · cites this paper as [41]
Citations
Cites
CHARMM: A program for macromolecular energy, minimization, and dynamics calculations
Brooks, B. R., Bruccoleri, R. E., Olafson, B. D., States, D. J., Swaminathan, S., & Karplus, M. (1983) · Journal of Computational Chemistry · doi:10.1002/jcc.540040211 · Cited by 14,944 · cited 1×
“Final energy minimization of all hMC4R-agonist complexes was performed using the CHARMm (45) potential with ε=10, and using the adopted-basis NewtonRaphson method (50 iterations).”
MethodCrystal Structure of Rhodopsin: A G Protein-Coupled Receptor
Palczewski, K., Kumasaka, T., Hori, T., Behnke, C. A., Motoshima, H., Fox, B. A., Trong, I. L., Teller, D. C., Okada, T., Stenkamp, R. E., et al. (2000) · Science · doi:10.1126/science.289.5480.739 · Cited by 5,637 · cited 2×
“However, among all GPCRs, a crystal structure has been determined only for rhodopsin, and only in its inactive state (23,24).”
BackgroundBallesteros, J. A., & Weinstein, H. (1995) · Methods in Neurosciences · doi:10.1016/s1043-9471(05)80049-7 · Cited by 2,999
Principles of docking: An overview of search algorithms and a guide to scoring functions
Halperin, I., Ma, B., Wolfson, H., & Nussinov, R. (2002) · Proteins: Structure, Function, and Bioinformatics · doi:10.1002/prot.10115 · Cited by 1,294 · cited 1×
“Finally, ligand docking is a complicated problem (28).”
BackgroundRequirement of Rigid-Body Motion of Transmembrane Helices for Light Activation of Rhodopsin
Farrens, D. L., Altenbach, C., Yang, K., Hubbell, W. L., & Khorana, H. G. (1996) · Science · doi:10.1126/science.274.5288.768 · Cited by 1,179 · cited 1×
“First, the active, agonist-bound conformation of GPCRs differs from the inactive state, especially in the position of transmembrane helix (TM) 6 (27).”
BackgroundStructure of Bovine Rhodopsin in a Trigonal Crystal Form
Li, J., Edwards, P. C., Burghammer, M., Villa, C., & Schertler, G. F. X. (2004) · Journal of Molecular Biology · doi:10.1016/j.jmb.2004.08.090 · Cited by 723 · cited 5×
“However, an experimental structure has been obtained only for the inactive state of bovine rhodopsin with bound inverse agonist, 11cisretinal (23,24).”
BackgroundMethodInfluentialSawyer, T. K., Sanfilippo, P. J., Hruby, V. J., Engel, M. H., Heward, C. B., Burnett, J. B., & Hadley, M. E. (1980) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.77.10.5754 · Cited by 575 · cited 1×
“The slightly different orientation for D-Phe7 relative to its L-enatiomer inside the pocket may be responsible for the greater potency and prolonged activity of NDP-MSH, relative toα-MSH (36,50) and for the larger effect of W258A mutation on the binding affinity and potency ofα-MSH relative to NDP-MSH (37).”
BackgroundGantz, I., & Fong, T. M. (2003) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00434.2002 · Cited by 466 · cited 5×
“(MC2R), exocrine secretion (MC5R), energy homeostasis, penile erection (MC3R and MC4R) and many others (1,5,6).”
BackgroundMethodInfluentialSelf-citationAgRP(83-132) Acts as an Inverse Agonist on the Human-Melanocortin-4 Receptor
Nijenhuis, W. A. J. (2001) · Molecular Endocrinology · doi:10.1210/me.15.1.164 · Cited by 406
Hrubu, V. J., Lu, D., Sharma, S. D., de L. Castrucci, A., Kesterson, R. A., Al-Obeidi, F. A., Hadley, M. E., & Cone, R. D. (1995) · Journal of Medicinal Chemistry · doi:10.1021/jm00018a005 · Cited by 348
Güntert, P., & Wüthrich, K. (1991) · Journal of Biomolecular NMR · doi:10.1007/bf02192866 · Cited by 328 · cited 5×
“The homology modeling of the agonist-bound state of hMC4R (residues 29-321), was accomplished here similarly using the program DIANA (41), which calculates a set of structures satisfying the imposed distance and angle constraints.”
MethodInfluentialNew aspects on the melanocortins and their receptors
Wikberg, J. E. S., Muceniece, R., Mandrika, I., Prusis, P., Lindblom, J., Post, C., & Skottner, A. (2000) · Pharmacological Research · doi:10.1006/phrs.2000.0725 · Cited by 319 · cited 5×
“5 Å) and 5-11 (∼12 Å), are compatible with formation of the corresponding disulfide or lactam bridges in other cyclic peptide agonists, such as Ac-cyclo[Cys3,Nle10,D-Nal7,Cys11]α-MSH(3-11) NH2, Ac-cyclo[Cys4,D-Nal7,Cys11]α-MSH(4-11)NH (60,61), Ac-Nle4 2-cyclo[D-Orn5,Glu8] α-MSH(4-11)NH (62) and Ac-Nle4-cyclo[Asp52 ,D-…”
BackgroundMethodInfluentialComparative protein structure modeling by iterative alignment, model building and model assessment
John, B. (2003) · Nucleic Acids Research · doi:10.1093/nar/gkg460 · Cited by 316 · cited 1×
“Indeed, homology modeling is a well-established technique (25) that currently works best for GPCRs (26).”
BackgroundA role for the melanocortin 4 receptor in sexual function
Van der Ploeg, L. H. T., Martin, W. J., Howard, A. D., Nargund, R. P., Austin, C. P., Guan, X., Drisko, J., Cashen, D., Sebhat, I., Patchett, A. A., et al. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.172378699 · Cited by 303 · cited 8×
“5 Å) and 5-11 (∼12 Å), are compatible with formation of the corresponding disulfide or lactam bridges in other cyclic peptide agonists, such as Ac-cyclo[Cys3,Nle10,D-Nal7,Cys11]α-MSH(3-11) NH2, Ac-cyclo[Cys4,D-Nal7,Cys11]α-MSH(4-11)NH (60,61), Ac-Nle4 2-cyclo[D-Orn5,Glu8] α-MSH(4-11)NH (62) and Ac-Nle4-cyclo[Asp52 ,D-…”
BackgroundInfluentialSelf-citationElectron crystallography reveals the structure of metarhodopsin I
Ruprecht, J. J., Mielke, T., Vogel, R., Villa, C., & Schertler, G. F. (2004) · The EMBO Journal · doi:10.1038/sj.emboj.7600374 · Cited by 298 · cited 11×
“Second, the sequence alignment of rhodopsin and other GPCRs is not obvious in the region of the nonregular loops and at helical distortions, such as the α-aneurisms (the insertion of an extra-residue in a helical turn)) present in TM2 and TM5, in the rhodopsin structure, which may be absent in other GPCRs. Finally, li…”
BackgroundInfluentialThe G-Protein Linked Receptor Facts Book
Watson, S. P., & Arkinstall, S. (1994) · Cited by 287
.alpha.-Melanotropin: the minimal active sequence in the frog skin bioassay
Hruby, V. J., Wilkes, B. C., Hadley, M. E., Al-Obeidi, F., Sawyer, T. K., Staples, D. J., DeVaux, A. E., Dym, O., & Castrucci, A. M. D. L. (1987) · Journal of Medicinal Chemistry · doi:10.1021/jm00394a033 · Cited by 271 · cited 3×
“Both ligands were first docked manually into the binding pocket of hMC4R to satisfy the following criteria: (1) a similar spatial arrangement of common pharmacophore groups in THIQ and MB243; (2) interaction of most functionally important groups of the ligands (especially, the central aromatic ring and N-terminal N+ g…”
BackgroundMethodDeBlasi, A., O'Reilly, K., & Motulsky, H. J. (1989) · Trends in Pharmacological Sciences · doi:10.1016/0165-6147(89)90266-6 · Cited by 253 · cited 1×
“To calculate Ki values the equation Ki = Kd = IC50— [radioligand] was used (39).”
MethodHaskell-Luevano, C., & Monck, E. K. (2001) · Regulatory Peptides · doi:10.1016/s0167-0115(01)00234-8 · Cited by 252 · cited 3×
“AGRP acts as an inverse agonist, reducing the elevated basal activity of MC4R (13-17).”
BackgroundResultYeo, G. S. H. (2003) · Human Molecular Genetics · doi:10.1093/hmg/12.5.561 · Cited by 242 · cited 7×
“5 Å) and 5-11 (∼12 Å), are compatible with formation of the corresponding disulfide or lactam bridges in other cyclic peptide agonists, such as Ac-cyclo[Cys3,Nle10,D-Nal7,Cys11]α-MSH(3-11) NH2, Ac-cyclo[Cys4,D-Nal7,Cys11]α-MSH(4-11)NH (60,61), Ac-Nle4 2-cyclo[D-Orn5,Glu8] α-MSH(4-11)NH (62) and Ac-Nle4-cyclo[Asp52 ,D-…”
BackgroundInfluentialSrinivasan, S., Lubrano-Berthelier, C., Govaerts, C., Picard, F., Santiago, P., Conklin, B. R., & Vaisse, C. (2004) · Journal of Clinical Investigation · doi:10.1172/jci200421927 · Cited by 235 · cited 2×
“In this case, their central tetrapeptide fragments (indicated in bold) structurally match each other, and the functionally important Arg18 of the N-terminus, whose mutations are associated with obesity (70), interacts with the functionally important acidic residues from TM3 of hMC4R (Figure 7).”
BackgroundSebhat, I. K., Martin, W. J., Ye, Z., Barakat, K., Mosley, R. T., Johnston, D. B. R., Bakshi, R., Palucki, B., Weinberg, D. H., MacNeil, T., et al. (2002) · Journal of Medicinal Chemistry · doi:10.1021/jm025539h · Cited by 193
Self-citationFunctional Characterization of Melanocortin-4 Receptor Mutations Associated with Childhood Obesity
Tao, Y.-X., & Segaloff, D. L. (2003) · Endocrinology · doi:10.1210/en.2003-0524 · Cited by 186 · cited 1×
“Mammals with a defective MC4R gene, which is expressed in the brain, are characterized by obese phenotype and increased food intake (10-12).”
BackgroundActivation of G-protein-coupled receptors: a common molecular mechanism
KARNIK, S., GOGONEA, C., PATIL, S., SAAD, Y., & TAKEZAKO, T. (2003) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2003.09.007 · Cited by 185 · cited 1×
“This model of the active conformation of μ-receptor can be used as a structural template for the modeling of other rhodopsin-like GPCRs that apparently share common activation mechanism and similar active conformations (34,35).”
BackgroundAl-Obeidi, F., Hadley, M. E., Pettitt, B. M., & Hruby, V. J. (1989) · Journal of the American Chemical Society · doi:10.1021/ja00191a044 · Cited by 184
Recognition of Privileged Structures by G-Protein Coupled Receptors
Bondensgaard, K., Ankersen, M., Thøgersen, H., Hansen, B. S., Wulff, B. S., & Bywater, R. P. (2004) · Journal of Medicinal Chemistry · doi:10.1021/jm0309452 · Cited by 181 · cited 1×
“Recently a number of small-molecule MC4R agonists and antagonists have been synthesized using “privileged structures” formerly employed in other GPCR ligands (21,22).”
BackgroundPogozheva, I. D., Lomize, A. L., & Mosberg, H. I. (1998) · Biophysical Journal · doi:10.1016/s0006-3495(98)77552-6 · Cited by 177 · cited 1×
“The inactive state of hMC4R (SwissProt accession code P32245) has recently been modeled from the rhodopsin crystal structure (24) by iterative distance geometry refinement (33), an approach described and tested previously (29-31,40).”
MethodSelf-citationMolecular Determinants of Ligand Binding to the Human Melanocortin-4 Receptor
Yang, Y.-K., Fong, T. M., Dickinson, C. J., Mao, C., Li, J.-Y., Tota, M. R., Mosley, R., Van der Ploeg, L. H. T., & Gantz, I. (2000) · Biochemistry · doi:10.1021/bi001684q · Cited by 170 · cited 3×
“The slightly different orientation for D-Phe7 relative to its L-enatiomer inside the pocket may be responsible for the greater potency and prolonged activity of NDP-MSH, relative toα-MSH (36,50) and for the larger effect of W258A mutation on the binding affinity and potency ofα-MSH relative to NDP-MSH (37).”
BackgroundMethodSelf-citationSawyer, T. K., Hruby, V. J., Darman, P. S., & Hadley, M. E. (1982) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.79.6.1751 · Cited by 163
Pogozheva, I. D., Lomize, A. L., & Mosberg, H. I. (1997) · Biophysical Journal · doi:10.1016/s0006-3495(97)78842-8 · Cited by 156 · cited 2×
“The inactive state of hMC4R (SwissProt accession code P32245) has recently been modeled from the rhodopsin crystal structure (24) by iterative distance geometry refinement (33), an approach described and tested previously (29-31,40).”
BackgroundMethodSelf-citationKask, A., Mutulis, F., Muceniece, R., Pähkla, R., Mutule, I., Wikberg, J. E. S., Rägo, L., & Schiöth, H. B. (1998) · Endocrinology · doi:10.1210/endo.139.12.6352 · Cited by 155
“The role of melanocortins in body weight regulation: opportunities for the treatment of obesity”
MacNeil, D. J., Howard, A. D., Guan, X.-M., Fong, T. M., Nargund, R. P., Bednarek, M. A., Goulet, M. T., Weinberg, D. H., Strack, A. M., Marsh, D. J., et al. (2002) · European Journal of Pharmacology · doi:10.1016/s0014-2999(02)01989-1 · Cited by 152 · cited 7×
“5 Å) and 5-11 (∼12 Å), are compatible with formation of the corresponding disulfide or lactam bridges in other cyclic peptide agonists, such as Ac-cyclo[Cys3,Nle10,D-Nal7,Cys11]α-MSH(3-11) NH2, Ac-cyclo[Cys4,D-Nal7,Cys11]α-MSH(4-11)NH (60,61), Ac-Nle4 2-cyclo[D-Orn5,Glu8] α-MSH(4-11)NH (62) and Ac-Nle4-cyclo[Asp52 ,D-…”
BackgroundInfluentialSelf-citationReceptor activation: what does the rhodopsin structure tell us?
Meng, E. C., & Bourne, H. R. (2001) · Trends in Pharmacological Sciences · doi:10.1016/s0165-6147(00)01825-3 · Cited by 152 · cited 1×
“This model of the active conformation of μ-receptor can be used as a structural template for the modeling of other rhodopsin-like GPCRs that apparently share common activation mechanism and similar active conformations (34,35).”
BackgroundYang, Y.-K., Dickinson, C., Haskell-Luevano, C., & Gantz, I. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.37.23000 · Cited by 143
Self-citationDiscovery of novel melanocortin4 receptor selective MSH analogues
Schiöth, H. B., Mutulis, F., Muceniece, R., Prusis, P., & Wikberg, J. E. S. (1998) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0701804 · Cited by 137 · cited 1×
“5 Å) and 5-11 (∼12 Å), are compatible with formation of the corresponding disulfide or lactam bridges in other cyclic peptide agonists, such as Ac-cyclo[Cys3,Nle10,D-Nal7,Cys11]α-MSH(3-11) NH2, Ac-cyclo[Cys4,D-Nal7,Cys11]α-MSH(4-11)NH (60,61), Ac-Nle4 2-cyclo[D-Orn5,Glu8] α-MSH(4-11)NH (62) and Ac-Nle4-cyclo[Asp52 ,D-…”
BackgroundAgouti and Agouti-related Protein: Analogies and Contrasts
Dinulescu, D. M., & Cone, R. D. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.10.6695 · Cited by 134
Role of melanocortins in the central control of feeding
Vergoni, A. V., & Bertolini, A. (2000) · European Journal of Pharmacology · doi:10.1016/s0014-2999(00)00538-0 · Cited by 134 · cited 7×
“5 Å) and 5-11 (∼12 Å), are compatible with formation of the corresponding disulfide or lactam bridges in other cyclic peptide agonists, such as Ac-cyclo[Cys3,Nle10,D-Nal7,Cys11]α-MSH(3-11) NH2, Ac-cyclo[Cys4,D-Nal7,Cys11]α-MSH(4-11)NH (60,61), Ac-Nle4 2-cyclo[D-Orn5,Glu8] α-MSH(4-11)NH (62) and Ac-Nle4-cyclo[Asp52 ,D-…”
BackgroundInfluentialMolecular Genetics of Human Obesity‐Associated MC4R Mutations
LUBRANO‐BERTHELIER, C., CAVAZOS, M., DUBERN, B., SHAPIRO, A., LE STUNFF, C., ZHANG, S., PICART, F., GOVAERTS, C., FROGUEL, P., BOUGNÈRES, P., et al. (2003) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2003.tb03161.x · Cited by 119 · cited 7×
“5 Å) and 5-11 (∼12 Å), are compatible with formation of the corresponding disulfide or lactam bridges in other cyclic peptide agonists, such as Ac-cyclo[Cys3,Nle10,D-Nal7,Cys11]α-MSH(3-11) NH2, Ac-cyclo[Cys4,D-Nal7,Cys11]α-MSH(4-11)NH (60,61), Ac-Nle4 2-cyclo[D-Orn5,Glu8] α-MSH(4-11)NH (62) and Ac-Nle4-cyclo[Asp52 ,D-…”
BackgroundInfluentialHomology modeling of opioid receptor-ligand complexes using experimental constraints
Pogozheva, I. D., Przydzial, M. J., & Mosberg, H. I. (2005) · The AAPS Journal · doi:10.1208/aapsj070243 · Cited by 113
Self-citationMetal Ion-mediated Agonism and Agonist Enhancement in Melanocortin MC1 and MC4 Receptors
Holst, B., Elling, C., & Schwartz, T. W. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m202103200 · Cited by 105 · cited 10×
“Sequence alignment of MCRs and rhodopsin (Figure 2) has been described previously (33).”
BackgroundInfluentialMelanocortin receptor-mediated mobilization of intracellular free calcium in HEK293 cells
MOUNTJOY, K. G., KONG, P. L., TAYLOR, J. A., WILLARD, D. H., & WILKISON, W. O. (2001) · Physiological Genomics · doi:10.1152/physiolgenomics.2001.5.1.11 · Cited by 104 · cited 7×
“5 Å) and 5-11 (∼12 Å), are compatible with formation of the corresponding disulfide or lactam bridges in other cyclic peptide agonists, such as Ac-cyclo[Cys3,Nle10,D-Nal7,Cys11]α-MSH(3-11) NH2, Ac-cyclo[Cys4,D-Nal7,Cys11]α-MSH(4-11)NH (60,61), Ac-Nle4 2-cyclo[D-Orn5,Glu8] α-MSH(4-11)NH (62) and Ac-Nle4-cyclo[Asp52 ,D-…”
BackgroundInfluentialInverse agonist activity of agouti and agouti-related protein
Chai, B.-X., Neubig, R. R., Millhauser, G. L., Thompson, D. A., Jackson, P. J., Barsh, G. S., Dickinson, C. J., Li, J.-Y., Lai, Y.-M., & Gantz, I. (2003) · Peptides · doi:10.1016/s0196-9781(03)00104-9 · Cited by 99 · cited 1×
“AGRP acts as an inverse agonist, reducing the elevated basal activity of MC4R (13-17).”
BackgroundSelf-citationHolder, J. R., Bauzo, R. M., Xiang, Z., & Haskell-Luevano, C. (2002) · Journal of Medicinal Chemistry · doi:10.1021/jm0104872 · Cited by 98
Cai, M., Cai, C., Mayorov, A. V., Xiong, C., Cabello, C. M., Soloshonok, V. A., Swift, J. R., Trivedi, D., & Hruby, V. J. (2004) · Journal of Peptide Research · doi:10.1111/j.1399-3011.2003.00105.x · Cited by 91
Molecular Determinants of Melanocortin 4 Receptor Ligand Binding and MC4/MC3 Receptor Selectivity
Nickolls, S. A., Cismowski, M., Wang, X., Wolff, M., Conlon, P. J., & Maki, R. A. (2003) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.102.044974 · Cited by 85 · cited 5×
“In particular, THIQ and MB243 (Figure 1) were identified as potent MC4R agonists with >100 fold selectivity over MC1R, MC3R and MC5R (18,19).”
BackgroundInfluentialSiegrist, W., Drozdz, R., Cotti, R., Willard, D. H., Wilkison, W. O., & Eberle, A. N. (1997) · Journal of Receptors and Signal Transduction · doi:10.3109/10799899709036595 · Cited by 85
Hadley, M. E., Anderson, B., Heward, C. B., Sawyer, T. K., & Hruby, V. J. (1981) · Science · doi:10.1126/science.6973820 · Cited by 76 · cited 2×
“The slightly different orientation for D-Phe7 relative to its L-enatiomer inside the pocket may be responsible for the greater potency and prolonged activity of NDP-MSH, relative toα-MSH (36,50) and for the larger effect of W258A mutation on the binding affinity and potency ofα-MSH relative to NDP-MSH (37).”
BackgroundFowler, C. B., Pogozheva, I. D., LeVine, H., & Mosberg, H. I. (2004) · Biochemistry · doi:10.1021/bi036067r · Cited by 71
Self-citationThe role of melanocortins in body weight regulation: opportunities for the treatment of obesity
MacNeil, D. J., Howard, A. D., Guan, X.-M., Fong, T. M., Nargund, R. P., Bednarek, M. A., Goulet, M. T., Weinberg, D. H., Strack, A. M., Marsh, D. J., et al. (2002) · European Journal of Pharmacology · doi:10.1016/s0014-2999(02)01425-5 · Cited by 70
Self-citationPrūsis, P., Schiöth, H. B., Muceniece, R., Herzyk, P., Afshar, M., Hubbard, R. E., & Wikberg, J. E. S. (1997) · Journal of Molecular Graphics and Modelling · doi:10.1016/s1093-3263(98)00004-7 · Cited by 69 · cited 1×
“The resulting models with peptide agonists were different in atomic details from those in earlier studies (16,47,51-53).”
ResultYang, Y., Chen, M., Lai, Y., Gantz, I., Georgeson, K. E., & Harmon, C. M. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m201343200 · Cited by 68 · cited 1×
“Indeed L133M mutation in hMC4R converts D-Nal(2’)7-containing SHU9119 into an agonist (67).”
BackgroundSelf-citationHerpin, T. F., Yu, G., Carlson, K. E., Morton, G. C., Wu, X., Kang, L., Tuerdi, H., Khanna, A., Tokarski, J. S., Lawrence, R. M., et al. (2003) · Journal of Medicinal Chemistry · doi:10.1021/jm025600i · Cited by 66 · cited 1×
“The models can also be used for computational analysis of binding of many agonists that were not considered here (71-75)), for finding potential metal binding sites in MCRs (42,76,77), and for rational drug design.”
BackgroundFowler, C. B., Pogozheva, I. D., Lomize, A. L., LeVine, H., & Mosberg, H. I. (2004) · Biochemistry · doi:10.1021/bi048413q · Cited by 65
Self-citationRichardson, T. I., Ornstein, P. L., Briner, K., Fisher, M. J., Backer, R. T., Bíggers, C. K., Clay, M. P., Emmerson, P. J., Hertel, L. W., Hsiung, H. M., et al. (2004) · Journal of Medicinal Chemistry · doi:10.1021/jm0304109 · Cited by 62 · cited 1×
“The models can also be used for computational analysis of binding of many agonists that were not considered here (71-75)), for finding potential metal binding sites in MCRs (42,76,77), and for rational drug design.”
Solution structures of cyclic melanocortin agonists and antagonists by NMR
Ying, J., Kövér, K. E., Gu, X., Han, G., Trivedi, D. B., Kavarana, M. J., & Hruby, V. J. (2003) · Biopolymers · doi:10.1002/bip.10596 · Cited by 61 · cited 2×
“Our models are consistent with receptor-bound conformations of agonists that have been proposed previously (18,48,56-59).”
BackgroundMethodHaskell-Luevano, C., Nikiforovich, G., Sharma, S. D., Yang, Y.-K., Dickinson, C., Hruby, V. J., & Gantz, I. (1997) · Journal of Medicinal Chemistry · doi:10.1021/jm960845e · Cited by 60 · cited 2×
“The resulting models with peptide agonists were different in atomic details from those in earlier studies (16,47,51-53).”
ResultSelf-citationPan, K., Scott, M. K., Lee, D. H. S., Fitzpatrick, L. J., Crooke, J. J., Rivero, R. A., Rosenthal, D. I., Vaidya, A. H., Zhao, B., & Reitz, A. B. (2003) · Bioorganic & Medicinal Chemistry · doi:10.1016/s0968-0896(02)00428-5 · Cited by 58 · cited 1×
“The models can also be used for computational analysis of binding of many agonists that were not considered here (71-75)), for finding potential metal binding sites in MCRs (42,76,77), and for rational drug design.”
BackgroundA Three-Dimensional Model for the Interaction of MSH with the Melanocortin-1 Receptor
Prūsis, P., Frändberg, P., Muceniece, R., Kalvinsh, I., & Wikberg, J. E. S. (1995) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1995.1647 · Cited by 56 · cited 1×
“The resulting models with peptide agonists were different in atomic details from those in earlier studies (16,47,51-53).”
ResultHOLST, B., & SCHWARTZ, T. W. (2003) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2003.tb03156.x · Cited by 56
Heavier‐than‐air flying machines are impossible
Oliveira, L., Hulsen, T., Hulsik, D. L., Paiva, A. C. M., & Vriend, G. (2004) · FEBS Letters · doi:10.1016/s0014-5793(04)00320-5 · Cited by 55 · cited 11×
“Second, the sequence alignment of rhodopsin and other GPCRs is not obvious in the region of the nonregular loops and at helical distortions, such as the α-aneurisms (the insertion of an extra-residue in a helical turn)) present in TM2 and TM5, in the rhodopsin structure, which may be absent in other GPCRs. Finally, li…”
BackgroundInfluentialDeletions of the N‐terminal regions of the human melanocortin receptors
Schiöth, H. B., Petersson, S., Muceniece, R., Szardenings, M., & Wikberg, J. E. S. (1997) · FEBS Letters · doi:10.1016/s0014-5793(97)00593-0 · Cited by 53 · cited 1×
“Our modeling of hMC4R does not include the N-terminal fragment, which can be deleted without loss of receptor activity (69).”
BackgroundHaskell‐Luevano, C., Lim, S., Yuan, W., Cone, R. D., & Hruby, V. J. (2000) · Peptides · doi:10.1016/s0196-9781(99)00167-9 · Cited by 50
Chai, B.-X., Pogozheva, I. D., Lai, Y.-M., Li, J.-Y., Neubig, R. R., Mosberg, H. I., & Gantz, I. (2005) · Biochemistry · doi:10.1021/bi0478704 · Cited by 49
Self-citationLagerström, M. C., Kloviņš, J., Fredriksson, R., Frīdmanis, D., Haitina, T., Ling, M. K., Berglund, M. M., & Schiöth, H. B. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m307683200 · Cited by 48 · cited 11×
“Sequence alignment of MCRs and rhodopsin (Figure 2) has been described previously (33).”
BackgroundInfluentialAryl piperazine melanocortin MC4 receptor agonists
Dyck, B. P., Parker, J., Phillips, T., Carter, L., Murphy, B., Summers, R., Hermann, J., Baker, T. J., Cismowski, M., Saunders, J., et al. (2003) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(03)00796-0 · Cited by 47 · cited 1×
“The models can also be used for computational analysis of binding of many agonists that were not considered here (71-75)), for finding potential metal binding sites in MCRs (42,76,77), and for rational drug design.”
BackgroundPrūsis, P., Muceniece, R., Andersson, P. M., Post, C., Lundstedt, T., & Wikberg, J. E. S. (2001) · Biochimica et Biophysica Acta (BBA) - Protein Structure and Molecular Enzymology · doi:10.1016/s0167-4838(00)00249-1 · Cited by 46 · cited 1×
“The resulting models with peptide agonists were different in atomic details from those in earlier studies (16,47,51-53).”
ResultMelanocortin Signaling and Anorexia in Chronic Disease States
Wisse, B. E., Schwartz, M. W., & Cummings, D. E. (2003) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2003.tb03190.x · Cited by 46 · cited 1×
“On the other hand, MC4R antagonists that block the satiety-inducing effect of α-MSH could be helpful for treatment of anorexia or cancer cachexia (20).”
BackgroundHolder, J. R., Xiang, Z., Bauzo, R. M., & Haskell-Luevano, C. (2002) · Journal of Medicinal Chemistry · doi:10.1021/jm020296e · Cited by 46
Willoughby, C. A., Hutchins, S. M., Rosauer, K. G., Dhar, M. J., Chapman, K. T., Chicchi, G. G., Sadowski, S. J., Weinberg, D. H., Patel, S. S., Malkowitz, L., et al. (2002) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(01)00665-5 · Cited by 44 · cited 1×
“Recently a number of small-molecule MC4R agonists and antagonists have been synthesized using “privileged structures” formerly employed in other GPCR ligands (21,22).”
BackgroundSelf-citationPalucki, B. L., Park, M. K., Nargund, R. P., Ye, Z., Sebhat, I. K., Pollard, P. G., Kalyani, R. N., Tang, R., MacNeil, T., Weinberg, D. H., et al. (2004) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2004.10.020 · Cited by 44
Self-citationCharacterization of a novel binding partner of the melanocortin-4 receptor: attractin-like protein
HAQQ, A. M., RENÉ, P., KISHI, T., KHONG, K., LEE, C. E., LIU, H., FRIEDMAN, J. M., ELMQUIST, J. K., & CONE, R. D. (2003) · Biochemical Journal · doi:10.1042/bj20031241 · Cited by 42 · cited 7×
“5 Å) and 5-11 (∼12 Å), are compatible with formation of the corresponding disulfide or lactam bridges in other cyclic peptide agonists, such as Ac-cyclo[Cys3,Nle10,D-Nal7,Cys11]α-MSH(3-11) NH2, Ac-cyclo[Cys4,D-Nal7,Cys11]α-MSH(4-11)NH (60,61), Ac-Nle4 2-cyclo[D-Orn5,Glu8] α-MSH(4-11)NH (62) and Ac-Nle4-cyclo[Asp52 ,D-…”
BackgroundInfluentialAnalogs of Lactam Derivatives of α-Melanotropin with Basic and Acidic Residues
Bednarek, M. A., MacNeil, T., Kalyani, R. N., Tang, R., der Ploeg, L. H. T. V., & Weinberg, D. H. (2000) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.2000.2589 · Cited by 32
Self-citationMutulis, F., Yahorava, S., Mutule, I., Yahorau, A., Liepinsh, E., Kopanchuk, S., Veikšina, S., Tārs, K., Belyakov, S., Mishnev, A., et al. (2004) · Journal of Medicinal Chemistry · doi:10.1021/jm0311285 · Cited by 32 · cited 4×
“THIQ has two nearly identical crystal structures, with an extended polypeptide backbone and piperidine and cyclohexane groups in the chair conformation (48).”
BackgroundMethodInfluentialCyclic lactam analogs of Ac-[Nle4].alpha.-MSH4-11-NH2
Sugg, E. E., Castrucci, A. M. D. L., Hadley, M. E., Binst, G. V., & Hruby, V. J. (1988) · Biochemistry · doi:10.1021/bi00421a029 · Cited by 30 · cited 1×
“5 Å) and 5-11 (∼12 Å), are compatible with formation of the corresponding disulfide or lactam bridges in other cyclic peptide agonists, such as Ac-cyclo[Cys3,Nle10,D-Nal7,Cys11]α-MSH(3-11) NH2, Ac-cyclo[Cys4,D-Nal7,Cys11]α-MSH(4-11)NH (60,61), Ac-Nle4 2-cyclo[D-Orn5,Glu8] α-MSH(4-11)NH (62) and Ac-Nle4-cyclo[Asp52 ,D-…”
BackgroundColao, A., & Pivonello, C. (2022) · Encyclopedia of pathology · doi:10.1007/978-3-030-62345-6_5112 · Cited by 28
Ujjainwalla, F., Warner, D., Walsh, T. F., Wyvratt, M. J., Zhou, C., Yang, L., Kalyani, R. N., MacNeil, T., der Ploeg, L. H. T. V., Rosenblum, C. I., et al. (2003) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2003.09.026 · Cited by 26 · cited 1×
“The models can also be used for computational analysis of binding of many agonists that were not considered here (71-75)), for finding potential metal binding sites in MCRs (42,76,77), and for rational drug design.”
BackgroundSelf-citationModeling of α‐MSH conformations with implicit solvent
Prabhu, N. V., Perkyns, J. S., & Pettitt, B. M. (1999) · Journal of Peptide Research · doi:10.1034/j.1399-3011.1999.00113.x · Cited by 25
Nikiforovich, G. V., Sharma, S. D., Hadley, M. E., & Hruby, V. J. (1998) · Biopolymers · doi:10.1002/(sici)1097-0282(199809)46:3<155::aid-bip3>3.0.co;2-k · Cited by 23
Discovery and in vivo evaluation of new melanocortin-4 receptor-selective peptides
Nijenhuis, W. A. J., Kruijtzer, J. A. W., Wanders, N., Vrinten, D. H., Garner, K. M., Schaaper, W. M. M., Meloen, R. H., Gispen, W. H., Liskamp, R. M. J., & Adan, R. A. H. (2003) · Peptides · doi:10.1016/s0196-9781(03)00032-9 · Cited by 20 · cited 2×
“In contrast, the region around His6 is formed by polar and aliphatic residues (Leu44, Val46, Glu100, Ile103, Asp122, Ile125, Asp126, Asn285) and, therefore, can adopt both polar and aromatic side chains (64,65,68).”
BackgroundAsp10 in Lys-γ2-MSH determines selective activation of the melanocortin MC3 receptor
Oosterom, J., Burbach, J. P. H., Gispen, W. H., & Adan, R. A. H. (1998) · European Journal of Pharmacology · doi:10.1016/s0014-2999(98)00491-9 · Cited by 12
Melanocortin Tetrapeptides Modified at the N‐Terminus, His, Phe, Arg, and Trp Positions
Holder, J. R., & Haskell‐Luevano, C. (2003) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2003.tb03160.x · Cited by 9 · cited 23×
“In the binding pocket of hMC4R eitherα-MSH or NDP-MSH forms at least 7 H-bonds with receptor residues: His264 (TM6) with the carboxylate group of Asp5 and carbonyl of Trp9; Glu100 (TM2) with the imidazole group of His6; Asp122 and Asp126 with the guanidium group of Arg8, Asp126 (TM3) with the amide group of L,D-Phe7;…”
BackgroundInfluential
Research works printed but not linked: 44
- Wikberg J. E., 2000, Pharmacol. Res. 42, 393−420.
- Haqq A. M., 2003, Biochem. J., 376
- Van der Ploeg L. H., 2002, Proc. Natl. Acad. Sci. U.S.A. 99
- Yeo G. S., 2003, Hum. Mol. Genet. 12, 561−574.
- Tao Y. X., 2003, Endocrinology 144, 4544−4551.
- Nijenhuis W. A., 2001, Mol. Endocrinol. 15, 164−171.
- Chai B. X., 2003, Peptides 24, 603−609.
- Palucki B. L., 2005, Bioorg. Med. Chem. Lett., 15
- Wisse B. E., 2003, Ann. N.Y. Acad. Sci. 994, 275−281.
- Willoughby C. A., 2002, Bioorg. Med. Chem. Lett., 12, 96
- Palczewski K., 2000, Science 289, 739−745.
- Li J., 2004, J. Mol. Biol., 343
- John B., 2003, Nucleic Acids Res. 31, 3982−3992.
- Farrens D. L., 1996, Science 274, 768−770.
- Halperin I., 2002, Proteins 47, 409−443.
- Pogozheva I. D., 1997, Biophys. J. 72
- Fowler C., 2004, Biochemistry 43, 8700−8710.
- Fowler C. B., 2004, Biochemistry 43, 15796−15810.
- Chai B.-X., 2005, Biochemistry 44, 3418−3431.
- Meng E. C., 2001, Trends Pharmacol. Sci. 22, 587−593.
- Karnik S. S., 2003, Trends Endocrinol. Metab. 14, 431−437.
- Hadley M. E., 1981, Science 213, 1025−1027.
- Yang Y.-K., 2000, Biochemistry 39, 14900−14911.
- Yang Y.-K., 1997, J. Biol. Chem., 272
- DeBlasi A., 1989, Trends Pharmacol. Sci. 10, 227−229.
- Sawyer T. K., 1982, Proc. Natl. Acad. Sci. U.S.A. 79
- Obeidi F., 1989, J. Am. Chem. Soc., 111
- Haskell-Luevano C., 1997, J. Med. Chem., 40
- Sawyer T. K., 1980, Proc. Natl. Acad. Sci. U.S.A. 77
- Prusis P., 1995, Biochem. Biophys. Res. Commun. 210, 205−210.
- Hruby V. J., 1995, J. Med. Chem., 38
- Nikiforovich G. V., 1998, Biopolymers 46, 155−167.
- Ying J., 2003, Biopolymers 71, 696−716.
- Cai M., 2004, J. Pept. Res., 63
- Kask A., 1998, Endocrinology 139, 5006−5014.
- Sugg E. E., 1988, Biochemistry 27, 8181−8188.
- Haskell-Luevano C., 2000, Peptides, 21, 57
- Nijenhuis W. A., 2003, Peptides 24, 271−280.
- Yang Y., 2002, J. Biol. Chem., 277
- Holder J. R., 2002, J. Med. Chem., 45
- Herpin T. F., 2003, Chem. 46, 1123−1126.
- Pan K., 2003, Chem. 11, 185−192.
- Richardson T. I., 2004, J. Med. Chem, 47
- Ballesteros J. A., 1995, Methods Neurosci. 25, 366−428.
Cited by
The Melanocortin-4 Receptor: Physiology, Pharmacology, and Pathophysiology
Tao, Y.-X. (2010) · Endocrine Reviews · doi:10.1210/er.2009-0037 · Cited by 531
“identify how THIQ binds to the MC4R (326, 353, 354).”
BackgroundMutations in ligands and receptors of the leptin–melanocortin pathway that lead to obesity
Farooqi, I. S., & O'Rahilly, S. (2008) · Nature Clinical Practice Endocrinology & Metabolism · doi:10.1038/ncpendmet0966 · Cited by 291
“Neuropeptide ligands bind to the cavity within the transmembrane bundle and so result in a conformational change and receptor activation”
BackgroundStructure, function and regulation of the melanocortin receptors
Yang, Y. (2011) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2010.12.020 · Cited by 139
“Mutation of these residues to alanine resulted in significantly decrease in endogenous agonist binding and receptor signaling, suggesting that these residues are also involved in melanocortin orthosteric binding (Fleck et al., 2005; Haskell-Luevano et al., 2001; Nickolls et al., 2003; Pogozheva et al., 2005; Yang et a…”
BackgroundInfluentialTargeting melanocortin receptors: an approach to treat weight disorders and sexual dysfunction
Wikberg, J. E. S., & Mutulis, F. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2331 · Cited by 139
“Basis for ligand binding Much attention has been given to computational molecular modelling of the melanocortin receptors, but the results are contradictory as the melanocortin binding pocket was placed at grossly different locations in different studie”
ResultEvolution of POMC: origin, phylogeny, posttranslational processing, and the melanocortins
Dores, R. M., & Baron, A. J. (2011) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2010.05928.x · Cited by 127
Metadata
- Authors
- Pogozheva, I. D., Chai, B.-X., Lomize, A. L., Fong, T. M., Weinberg, D. H., Nargund, R. P., Mulholland, M. W., Gantz, I., & Mosberg, H. I.
- Affiliations
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- Venue
- Biochemistry
- Publisher
- American Chemical Society (ACS)
- Published
- 2005-08-01
- Volume
- 44
- Issue
- 34
- Pages
- 11329-11341
- ISSN
- 0006-2960 (ISSN-L)
- 1520-4995
- PMC
- PMC2532597
- OpenAlex
- W1995624852
- Cited by
- 92
- References
- 81
- Citations by year
- 2024: 2 · 2023: 2 · 2022: 2 · 2021: 2 · 2020: 1 · 2019: 3 · 2018: 2 · 2017: 8 · 2016: 4 · 2015: 4 · 2014: 7 · 2013: 7 · 2012: 7
- FWCI
- 2.77
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Biochemistry (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- University of Michigan
- National Institute on Drug Abuse (R01DA003910, DA03910)
- National Institute of Diabetes and Digestive and Kidney Diseases (P30DK034933, P30 DK 34933, R01DK054032, DK054032)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Receptor Mechanisms and Signaling
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuropeptides and Animal Physiology
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Keywords
- melanocortin-4 receptor, ligand-receptor interactions, peptide agonists, NDP-MSH, alanine scanning, transmembrane helices, disulfide bonds, pharmacophore, binding affinity, agonist potency
- MeSH terms
- Cyclic AMP, Amino Acid Sequence, Binding Sites, Humans, Models, Molecular, Molecular Sequence Data, Peptides, Piperazines, Piperidines, Recombinant Proteins, Rhodopsin, Transfection, Mutagenesis, Site-Directed, Sequence Alignment, Sequence Homology, Amino Acid, Protein Structure, Secondary, Receptor, Melanocortin, Type 4
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.